CC BY-NC-ND 4.0 · Thromb Haemost 2017; 117(07): 1326-1337
DOI: 10.1160/TH16-10-0793
Coagulation and Fibrinolysis
Schattauer GmbH

The management of acute venous thromboembolism in clinical practice

Results from the European PREFER in VTE Registry
Alexander T. Cohen
1   Guys and St Thomas’ Hospitals NHS Foundation Trust, King’s College, London, UK
Anselm K. Gitt
2   Herzzentrum Ludwigshafen Med. Klinik B, Ludwigshafen, Germany
Rupert Bauersachs
3   Klinikum Darmstadt GmbH, Darmstadt, Germany
4   Center of Thrombosis and Haemostasis, University of Mainz, Mainz, Germany
Eva-Maria Fronk
5   Daiichi Sankyo Europe GmbH, Munich, Germany
Petra Laeis
5   Daiichi Sankyo Europe GmbH, Munich, Germany
Patrick Mismetti
6   CHU Saint-Etienne Hopital Nord, Saint Etienne Cedex 2, France
Manuel Monreal
7   Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
Stefan N. Willich
8   Charité – Universitätsmedizin Berlin, Germany
Peter Bramlage
9   Institute for Pharmacology and Preventive Medicine, Mahlow, Germany
Giancarlo Agnelli
10   University of Perugia, Santa Maria della Misericordia Hospital, Perugia, Italy
the PREFER in VTE Scientific Steering Committee and the PREFER in VTE Investigators › Author Affiliations
Financial Support:This study was funded by Daiichi Sankyo Europe GmbH, Munich, Germany.
Further Information

Publication History

Received: 18 October 2016

Accepted after major revision: 22 March 2017

Publication Date:
28 November 2017 (online)


Venous thromboembolism (VTE) is a significant cause of morbidity and mortality in Europe. Data from real-world registries are necessary, as clinical trials do not represent the full spectrum of VTE patients seen in clinical practice. We aimed to document the epidemiology, management and outcomes of VTE using data from a large, observational database. PREFER in VTE was an international, non-interventional disease registry conducted between January 2013 and July 2015 in primary and secondary care across seven European countries. Consecutive patients with acute VTE were documented and followed up over 12 months. PREFER in VTE included 3,455 patients with a mean age of 60.8 ± 17.0 years. Overall, 53.0% were male. The majority of patients were assessed in the hospital setting as inpatients or outpatients (78.5%). The diagnosis was deep-vein thrombosis (DVT) in 59.5% and pulmonary embolism (PE) in 40.5%. The most common comorbidities were the various types of cardiovascular disease (excluding hypertension; 45.5%), hypertension (42.3%) and dyslipidaemia (21.1%). Following the index VTE, a large proportion of patients received initial therapy with heparin (73.2%), almost half received a vitamin K antagonist (48.7%) and nearly a quarter received a DOAC (24.5%). Almost a quarter of all presentations were for recurrent VTE, with >80% of previous episodes having occurred more than 12 months prior to baseline. In conclusion, PREFER in VTE has provided contemporary insights into VTE patients and their real-world management, including their baseline characteristics, risk factors, disease history, symptoms and signs, initial therapy and outcomes.

Author contributions

All authors have contributed to the design of the registry and/or the preparation of the manuscript. EMF was responsible for the analysis of data. ATC and PB drafted the first version of the manuscript and the remaining authors made substantial revisions to the manuscript. All authors have approved the version to be published. Apart from the selection of the countries, all design aspects were decided by the scientific Steering Committee and executed by independent Contract Research organizations.

  • References

  • 1 Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscl Thromb Vasc Biol 2008; 28: 370-372.
  • 2 Cohen AT, Agnelli G, Anderson FA. et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98: 756-764.
  • 3 Suarez Fernandez C, Gonzalez-Fajardo JA, Monreal Bosch M. et al. Computerized registry of patients with thromboembolic disease in Spain (RIETE): background, objectives, methods, and preliminary results. Rev Clin Espan 2003; 203: 68-73.
  • 4 Hach-Wunderle V, Bauersachs R, Gerlach HE. et al. Post-thrombotic syndrome 3 years after deep venous thrombosis in the Thrombosis and Pulmonary Embolism in Out-Patients (TULIPA) PLUS Registry. J Vasc Surg Venous Lymph Dis 2013; 1: 5-12.
  • 5 Agnelli G, Gitt AK, Bauersachs R. et al. The management of acute venous thromboembolism in clinical practice – study rationale and protocol of the European PREFER in VTE Registry. Thrombosis J 2015; 13: 41.
  • 6 Pisters R, Lane DA, Nieuwlaat R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100.
  • 7 Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the S et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692-694.
  • 8 van Es N, Coppens M, Schulman S. et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124: 1968-1975.
  • 9 Heit JA. Venous thromboembolism epidemiology: implications for prevention and management. Semin Thromb Hemost 2002; 28 (Suppl. 02) 3-13.
  • 10 Martinez C, Cohen AT, Bamber L. et al. Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer. Thromb Haemost 2014; 112: 255-263.
  • 11 Schulman S, Kakkar AK, Goldhaber SZ. et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129: 764-772.
  • 12 Mason C. Venous thromboembolism: a chronic illness. J Cardiovasc Nurs 2009; 24 (Suppl. 06) S4-S7.
  • 13 Maestre A, Sanchez R, Rosa V. et al. Clinical characteristics and outcome of inpatients versus outpatients with venous thromboembolism: findings from the RIETE Registry. Eur J Intern Med 2010; 21: 377-382.
  • 14 GARFIELD-VTE Registry Thrombosis Research Insitute, Providing Excellence in Thrombosis Research. Available at: Accessed May 27, 2015
  • 15 Miniati M, Cenci C, Monti S. et al. Clinical presentation of acute pulmonary embolism: survey of 800 cases. PloS one 2012; 7: e30891.
  • 16 Pollack CV, Schreiber D, Goldhaber SZ. et al. Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry). J Am Coll Cardiol 2011; 57: 700-706.
  • 17 Kearon C, Akl EA, Ornelas J. et al. Antithrombotic therapy for vte disease: Chest guideline and expert panel report. Chest 2016; 149: 315-352.
  • 18 Di Nisio M, Raskob G, Buller HR. et al. Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists. Thromb Haemost 2017; 117: 794-793.
  • 19 Kirchhof P, Benussi S, Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893-2962.
  • 20 Kooiman J, van Hagen N, Iglesias Del Sol A. et al. The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment. PloS one 2015; 10: e0122520.
  • 21 Riva N, Bellesini M, Di Minno MN. et al. Poor predictive value of contemporary bleeding risk scores during long-term treatment of venous thromboembolism. A multicentre retrospective cohort study. Thromb Haemost 2014; 112: 511-521.
  • 22 Klok FA, Hosel V, Clemens A. et al. Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. Eur Resp J 2016; 48: 1369-1376.
  • 23 Kirchhof P, Ammentorp B, Darius H. et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events--European Registry in Atrial Fibrillation (PREFER in AF). Europace 2014; 16: 6-14.
  • 24 Hokusai VTE Investigators. Buller HR, Decousus H. et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406-1415.
  • 25 Schulman S, Kearon C, Kakkar AK. et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352.
  • 26 Investigators E, Bauersachs R, Berkowitz SD. et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
  • 27 Investigators E-P, Buller HR, Prins MH. et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-1297.
  • 28 Agnelli G, Buller HR, Cohen A. et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799-808.
  • 29 van der Hulle T, Kooiman J, den Exter PL. et al. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 2014; 12: 320-328.
  • 30 Becattini C, Agnelli G, Prandoni P. et al. A prospective study on cardiovascular events after acute pulmonary embolism. Eur Heart J 2005; 26: 77-83.
  • 31 Sorensen HT, Horvath-Puho E, Pedersen L. et al. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 2007; 370: 1773-1779.